Open AccessOrally Bioavailable SERD Shows Promise in Certain Breast Cancer Patients
Author(s) -
Catlin Nalley
Publication year - 2021
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000734348.58210.24
Subject(s) - palbociclib , breast cancer , medicine , tolerability , fulvestrant , cancer , metastatic breast cancer , oncology , pharmacology , estrogen receptor , adverse effect